Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 8/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758326 | 0.91 | MAPK1 (0.52) | MAP4K4MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL5755117 | 0.86 | MAPK1 (0.51) | MAP4K4MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL5759347 | 0.85 | MAP4K4 (0.51) | MAP4K4MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL5758049 | 0.83 | MAPK1 (0.48) | MAP4K4MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL5758449 | 0.82 | MAPK1 (0.53) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5758213 | 0.82 | MAPK1 (0.46) | MAP4K4MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL6767095 | 0.81 | MAPK1 (0.47) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5758071 | 0.80 | MAP4K4 (0.52) | MAP4K4MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL5758412 | 0.79 | MAPK1 (0.48) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5757558 | 0.78 | MAPK1 (0.50) | MAP4K4MAPK1PIK3CAMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028729-B1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH 5-AZAQUINOXALINE-BASED COMPOUNDS | ZENTARIS GMBH (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6727252-B1 | THE SERINE/THREONINE KINASE FAMILY INCLUDES MEMBERS THAT REGULATE CELL GROWTH, MIGRATION, DIFFERENTIATION, GENE EXPRESSION, MUSCLE CONTRACTION, GLUCOSE METABOLISM, CELLULAR PROTEIN SYNTHESIS, AND REGULATION OF THE CELL CYCLE | ZENTARIS AG (DE) | 2004-04-27 | — | — | US | disclosed |
| US-6180631-B1 | PREVENTING AND TREATING SERINE/THREONINE PROTEIN KINASE-RELATED ABNORMAL CONDITIONS IN MAMMALS ASSOCIATED WITH AN ABERRATION IN A SIGNAL TRANSDUCTION PATHWAY SUCH AS CANCER OR A FIBROTIC DISORDER | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-01-30 | — | — | US | disclosed |
| EP-1028729-A2 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH 5-AZAQUINOXALINE-BASED COMPOUNDS | ASTA Medica Aktiengesellschaft (DE) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999017759-A2 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH 5-AZAQUINOXALINE-BASED COMPOUNDS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-04-15 | — | — | WO | disclosed |